Cardio Symp

Arkansas Cardiology Symposium

Registration Form







    If there are any issues regarding filling out the form please email Amy at awyles@arcard.org

    2024 SYMPOSIUM AGENDA

    7:00 a.m. Registration, Continental Breakfast, and Exhibits

    7:50 a.m. Welcome and Opening Remarks, Invocation
    Jay Geoghagan, MD, FACC
    David Jones, MD, FACC
    Steve Greer, MD, FACC, FACP

    8:00 a.m. Hypertension
    Dwight Chrisman, MD, FACC

    8:30 a.m. Aortic Aneurysm Diagnosis and Management
    Wesley Fiser, MD, FACC

    9:00 a.m. DAPT after PCI
    Tom Conley, MD, FACC, FSCAI

    9:30 a.m. Morning Break and Exhibits

    9:45 a.m. Exercise and Sports Cardiology
    Jay Geoghagan, MD, FACC

    10:15 a.m. Non-Surgical Structural Options – What the PCP Needs to Know
    Evan Watts, MD, FACC

    10:45 a.m. Women and Heart Disease
    Christen Johnson, MD

    11:15 a.m. Management of Chronic Coronary Disease
    Charles Caldwell, MD, FACC

    11:45 a.m. Lunch and Exhibits

    12:45 p.m. HFrEF
    Patrick Campbell, MD, FACC

    1:15 p.m. HFpEF
    Bernard Gojer, MD, FACC

    1:45 p.m. ECG Review
    Jeff Neuhauser, DO, FACC, FHRS

    2:15 p.m. Afternoon Break and Exhibits

    2:30 p.m. Afib
    Breck Sandvall, MD

    3:00 p.m. Nutrition
    Alex Orsini, MD, FACC

    3:30 p.m. Adjourn

    Objectives

    • Review ACC/AHA guidelines related to the treatment of poorly controlled hypertension.
    • Review options for hypertension management.
    • Discuss types of Aortopathy.
    • Review known causes of Aortopathy.
    • Discuss the appropriate duration of dual antiplatelet therapy after coronary stenting.
    • Review the data for short- and long-term dual anti-platelet therapy.
    • Discuss sports recommendations in post-COVID patients.
    • Know the rationale and suggested use of the AHA/ACC Eligibility and Disqualification Recommendations for Competitive Athletes.
    • Review the current technological advances in the interventional management ofstructural heart diseases, including minimally invasive heart valve interventionson aortic, mitral and tricuspid disease.
    • Discuss improvements to safety, quality and patient satisfaction surroundingnon-surgical structural procedures.
    • Discuss risk factors for Women with known coronary artery disease.
    • Evaluate treatment options for Women with known coronary artery disease.
    • Explain how managing health behaviors and risk factors are an important aspectof lowering the risk of cardiovascular disease.
    • Discuss exercise strategies for patients with known cardiac disease.
    • Review clinical treatment strategies to address patients with Heart Failure withReduced Ejection Fraction (HFrEF).
    • Assess the implications of new treatments for HFrEF.
    • Review clinical treatment strategies to address patients with Heart Failure withpreserved Ejection Fraction (HFpEF).
    • Assess medications used to treat HFpEF.
    • Review normal and abnormal ECG findings.
    • Determine appropriate treatment options for specific arrhythmias.
    • Review clinical literature relating to novel anticoagulant medications.
    • Discuss the complications of atrial fibrillation and the reasoning behind theprescribing of an anticoagulant.
    • Review Dietary trends and discuss the role they play in overall CardiovascularHealth.